Trial reportJournal of clinical hypertension (Greenwich, Conn.)2006
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- Recurrence of unilateral angioedema of the tongue: A case report.World journal of clinical cases · 2023Article
- Article
- Cutaneous Drug Reactions in the Elderly.Drugs & aging · 2017Review
- ACE inhibitor-associated intestinal angioedema in orthotopic heart transplantation.ESC heart failure · 2017Article
- Accurate estimation of protein/creatinine ratio on urine sample in CKD patients.Clinical and experimental nephrology · 2016Article
- Life-threatening ACE inhibitor-induced angio-oedema successfully treated with icatibant: a bradykinin receptor antagonist.BMJ case reports · 2015Article
- Propensity score methods for confounding control in nonexperimental research.Circulation. Cardiovascular quality and outcomes · 2013Article
- Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.Drug safety · 2012Article
- Effectiveness, safety and cost of drug substitution in hypertension.British journal of clinical pharmacology · 2010Article
- Cerebral angioedema associated with enalapril.British journal of clinical pharmacology · 2009Article
- Amlodipine-induced angioedema: An unusual complication of a common medication.Allergy & rhinology (Providence, R.I.)Article
- Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema.Allergy and asthma proceedingsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angioedema is a rare, potentially life-threatening condition that has been associated with angiotensin-converting enzyme inhibitors since their introduction in the 1980s. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest antihypertensive study conducted to date, randomized 42,418 participants to a diuretic (chlorthalidone), a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), or an alpha-blocker (doxazosin). Patients who developed angioedema were compared for baseline characteristics and changes in antihypertensive drug administration. Fifty-three participants developed angioedema during active follow-up: 55% were black, 60% men, and 70% were assigned to lisinopril (including 62% of black participants with angioedema), 15% to chlorthalidone, 9% to doxazosin, and 6% to amlodipine. Six percent occurred within a day of randomization and 23% within the first week. Over half did not have an increase in their assigned (blinded) antihypertensive drug before angioedema onset; 3 (6%) had a dose increase within a week before onset. One patient died following an angioedema episode. The occurrence of angioedema in the angiotensin-converting enzyme inhibitor arm corresponds with previously reported angioedema-angiotensin-converting enzyme inhibitor associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.